With its multiple sclerosis powerhouse Ocrevus expected to lose patent protection by the end of the decade, Roche is looking for ways to extend the market exclusivity for the top-selling drug in ...
FRANKFURT, April 2 (Reuters) - Roche (ROG.S), opens new tab said on Wednesday that a trial testing higher doses of its multiple sclerosis drug Ocrevus did not show an efficacy benefit over the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback